https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-07-04 / Front Mol Biosci 2022;9:889403
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-07-04 / Front Mol Biosci 2022;9:8894032022-07-04 00:00:002022-07-04 00:00:00Development of Molecular Mechanisms and Their Application on Oncolytic Newcastle Disease Virus in Cancer Therapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-06-17 / Pharm Res 2022 Aug;39(8):1851-1866
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-06-17 / Pharm Res 2022 Aug;39(8):1851-18662022-06-17 00:00:002022-06-17 00:00:00Dual Blockade of PD-1 and LAG3 Immune Checkpoints Increases Dendritic Cell Vaccine Mediated T Cell Responses in Breast Cancer Model
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-06-16 / BMJ Open 2022 Jun;12(6):e060431
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-06-16 / BMJ Open 2022 Jun;12(6):e0604312022-06-16 00:00:002022-06-16 00:00:00Safety and tumour-specific immunological responses of combined dendritic cell vaccination and anti-CD40 agonistic antibody treatment for patients with metastatic pancreatic cancer: protocol for a phase I, open-label, single-arm, dose-escalation study (REACtiVe-2 trial)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-06-04 / Cells 2022 Jun;11(11)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-06-04 / Cells 2022 Jun;11(11)2022-06-04 00:00:002022-06-04 00:00:00Forcing the Antitumor Effects of HSPs Using a Modulated Electric Field
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-06-03 / Cancer Immunol Res 2022 Jun;10(6):728-744
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-06-03 / Cancer Immunol Res 2022 Jun;10(6):728-7442022-06-03 00:00:002022-06-03 00:00:00Combination Neoantigen-Based Dendritic Cell Vaccination and Adoptive T-Cell Transfer Induces Antitumor Responses Against Recurrence of Hepatocellular Carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-05-31 / Eur Urol Focus 2022 May;8(3):651-653
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-05-31 / Eur Urol Focus 2022 May;8(3):651-6532022-05-31 00:00:002022-05-31 00:00:00Autologous Dendritic Vaccine Therapy in Metastatic Kidney Cancer: The ADAPT Trial and Beyond
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-04-28 / J Cancer Res Clin Oncol 2023 Apr;149(4):1425-1441
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-04-28 / J Cancer Res Clin Oncol 2023 Apr;149(4):1425-14412022-04-28 00:00:002022-04-28 00:00:00Efficacy and security of tumor vaccines for hepatocellular carcinoma: a systemic review and meta-analysis of the last 2 decades
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-04-28 / Eur J Cancer 2022 Jul;169:20-31
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-04-28 / Eur J Cancer 2022 Jul;169:20-312022-04-28 00:00:002022-04-28 00:00:00Autologous dendritic cells pulsed with allogeneic tumour cell lysate induce tumour-reactive T-cell responses in patients with pancreatic cancer: A phase I study
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-04-05 / PLoS One 2022;17(4):e0264896
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-04-05 / PLoS One 2022;17(4):e02648962022-04-05 00:00:002022-04-05 00:00:00Newcastle disease virus expressing an angiogenic inhibitor exerts an enhanced therapeutic efficacy in colon cancer model
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-03-10 / Ther Apher Dial 2022 Jun;26(3):537-547
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-03-10 / Ther Apher Dial 2022 Jun;26(3):537-5472022-03-10 00:00:002022-03-10 00:00:00Wilms‘ tumor 1 peptide-loaded dendritic cell vaccination in patients with relapsed or refractory acute leukemia
